Description

Buy Trodelvy For Sale In USA

What is Trodelvy?

Trodelvy (sacituzumab govitecan-hziy) is a targeted antibody-drug conjugate (ADC) that may be used to treat adults with the following cancers that have spread (metastasized) or cannot be removed by Buy Trodelvy For Sale In USA

• triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2 [TNBC]) who have received at least 2 prior treatments, including at least one for metastatic disease.
• hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who have previously received endocrine therapy and at least 2 additional treatments for metastatic disease
• bladder cancer and cancers of the urinary tract who have received a platinum-containing chemotherapy medicine and an immunotherapy medicine.

Trodelvy is an ADC that is designed to deliver anticancer medicine directly into cells with Trop-2 proteins. Research has found certain types of cancer cells contain more Trop-2 protein than noncancerous cells. Trodelvy For Sale Online

Trodelvy (sacituzumab govitecan-hziy) contains 3 different substances:

• sacituzumab, an antibody that looks for Trop-2
• an anticancer molecule, SN-38, which is a topoisomerase I inhibitor and the active metabolite of irinotecan
• and a linker that joins sacituzumab to SN-38.

Trodelvy works by binding to Trop-2-expressing cancer cells. It is then taken up by the cell and the linker is hydrolyzed (broken apart) releasing SN-38 directly into the cell. SN-38 interacts with the enzyme topoisomerase I, causing single-strand breaks and DNA damage, leading to cell death and decreased tumor growth.

For metastatic HR+/HER2- breast cancer in men and women who had previously received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting, Trodelvy is now recommended by the National Comprehensive Cancer Network (NCCN) as Category 1 or preferred treatment. Buy Trodelvy For Sale In USA

• An overall survival benefit of 3.2 months was reported with Trodelvy compared with single-agent chemotherapy (median OS: 14.4 months vs. 11.2 months; hazard ratio [HR]=0.79; 95% CI: 0.65-0.96; p=0.02).
• There was a 34% reduced risk of disease progression or death median PFS: 5.5 versus 4.0 months; HR: 0.66; 95% CI: 0.53-0.83; p=0.0003).
• 21% of those treated with Trodelvy versus 7% treated with single-agent chemotherapy were progression-free at one year.

Trodelvy was first FDA approved on April 22, 2020, under the accelerated approval designation for relapsed or refractory metastatic TNBC, and gained full approval for this indication on April 7, 2021. It was granted accelerated approval for metastatic urothelial cancer on April 13, 2021 (continued approval may be dependent on clinical trials showing a benefit) and full approval for metastatic HR+/HER2- breast cancer on February 3, 2023.

Warnings

Serious hypersensitivity and infusion-related reactions, including anaphylaxis, can occur with Trodelvy. Do not receive Trodelvy if you have had a severe allergic reaction to sacituzumab govitecan-hziy or any of the inactive ingredients in the injection.

Trodelvy carries a black box warning for severe or life-threatening neutropenia and diarrhea.

Trodelvy may cause nausea and vomiting, which can be severe. Your healthcare provider should prescribe antiemetic preventive treatment and withhold Trodelvy for patients with Grade 3 nausea or Grade 3-4 vomiting at the time of treatment. Buy Trodelvy For Sale In USA